Ethyl Pyruvate Attenuates Spinal Cord Ischemic Injury with a Wide Therapeutic Window through Inhibiting High-mobility Group Box 1 Release in Rabbits
Wang, Qiang M.D., Ph.D.*; Ding, Qian M.D.†; Zhou, Yiming M.D.†; Gou, Xingchun M.D.‡; Hou, Lichao Ph.D.*; Chen, Shaoyang M.D.*; Zhu, Zhenghua Ph.D.*; Xiong, Lize M.D., Ph.D.§
Background: Ethyl pyruvate (EP) has been reported to offer a protective effect against ischemic injury through its antiinflammatory action. The nuclear protein high-mobility group box 1 (HMGB1) can activate inflammatory pathways when released from ischemic cells. This study was designed to investigate the neuroprotective effect of EP against spinal cord ischemic injury and the potential role of HMGB1 in this process.
Methods: EP was administered at various time points before or after 20 min of spinal cord ischemia in male New Zealand rabbits. All animals were sacrificed at 72 h after reperfusion with modified Tarlov criteria, and the spinal cord segment (L4) was harvested for histopathological examination and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling staining. The HMGB1 levels in serum and spinal cord tissue were analyzed by enzyme-linked immunosorbent assay.
Results: The treatment of EP at 30 min before ischemia or at 6 h after reperfusion significantly improved the hind-limb motor function scores and increased the numbers of normal motor neurons, which was accompanied with reduction of the number of apoptotic neurons and levels of HMGB1 in serum and spinal cord tissue. The HMGB1 contents of spinal cord tissue correlated well with the numbers of apoptotic motor neurons in the anterior spinal cord at 72 h after reperfusion.
Conclusion: These results suggest that EP affords a strong protection against the transient spinal cord ischemic injury with a wide therapeutic window through inhibition of HMGB1 release.
ISCHEMIC spinal cord injury represents the main complication in surgical repair of thoracic and thoracoabdominal aneurisms and remains a persistent clinical problem. The development of paraparesis or paraplegia after aortic surgery can be classed as immediate or delayed. A primary cause of immediate spinal cord dysfunction is ischemia induced by temporary interruption of blood flow to the spinal cord during aortic cross-clamping. Delayed neurologic complications can develop during the period of reperfusion.1
Of the many pathophysiological events that may contribute to this delayed injury, postischemic inflammation and apoptosis have been suggested to contribute to the late stages of the reperfusion injury and to result in a worsening of neurologic outcome.2–4
Ethyl pyruvate (EP), a stable and lipophilic derivative of pyruvate, protects various tissue injuries, such as lethal sepsis and systemic inflammation.5
Recently, the protective effect of EP on ischemia–reperfusion (I/R) injury to brain and myocardium has been reported.6–9
So far, there are no studies attempting to describe the protective effect of this agent on spinal cord ischemia.
In addition, high-mobility group box 1 (HMGB1) was originally identified as a DNA-binding protein that functions as a structural cofactor critical for proper transcriptional regulation in somatic cells. There is a wealth of evidence to indicate that HMGB1 is massively released during the excitotoxicity-induced acute damaging process in the postischemic brain. The extracellular HMGB1 triggers inflammatory processes, suggesting that HMGB1 acts as a novel mediator that links excitotoxicity-induced acute damage and subsequent inflammatory processes in the postischemic brain.10–12
However, the contribution of HMGB1 to pathogenesis after spinal cord I/R are unknown.
Therefore, the objective of this study was to test the neuroprotective effect of EP in a rabbit spinal cord ischemia model of infrarenal aortic occlusion and to investigate the underlying mechanisms responsible for HMGB1 in terms of effective therapeutic windows. We hypothesized that EP could reduce spinal cord ischemic injury with a wide therapeutic window through inhibition of HMGB1 release. This hypothesis was based on previous observations that extracellular HMGB1 serves as a late cytokine-like mediator of systemic inflammation that provides a wider time frame for clinical intervention against progressive inflammatory disorders.13
This hypothesis was also based on the knowledge that EP inhibits HMGB1 secretion from human macrophages in a concentration-dependent fashion with an estimated effective concentration clinically achievable.14
Materials and Methods
Instrumentation of Animals
All experiments were performed on male New Zealand White rabbits weighing 2.2 to 2.5 kg. The animals were provided by the Experimental Animal Center of the Fourth Military Medical University, Xi’an, China. The animals were studied at Xijing Hospital, Fourth Military Medical University (Xi’an, China). The experimental protocol was approved by the Ethics Committee for Animal Experimentation, and all animals received humane care in compliance with the guidelines for Animal Experimentation of the Fourth Military Medical University (Xi’an, China), which was in accordance with the “Guide for the Care and Use of Laboratory Animals” published by the U.S. National Institutes of Health (NIH Publication No. 85–23, revised 1996). All efforts were made to minimize animal suffering and the number of animals used for this study.
The present study consisted of two experiments. In experiment I, 40 rabbits were randomly divided into 5 groups (n
= 8 each group): control, EP, EP-6 h, EP-12 h and EP-24h groups. The rabbits in the control group underwent only I/R. The rabbits in EP, EP-6 h, EP-12 h, and EP-24h groups intravenously received a dose of 40 mg/kg EP at 30 min before ischemia or at 6 h, 12 h, or 24 h after reperfusion, respectively. In experiment II, 24 rabbits were randomly divided into 3 groups (n
= 8 each group): sham, control, and EP groups. The animals in sham group only underwent the surgical procedure, but the aorta was not occluded. The rabbits in control and EP groups received Ringer’s solution (IV, 1 ml) and a dose of 40 mg/kg EP at 30 min before ischemia, respectively. EP (98% pure) was purchased from Sigma-Aldrich Co. (St. Louis, MO) and was prepared and injected in the form of Ringer’s ethyl pyruvate solution. The injection volume was 1 ml per dose. For the sake of minimizing the number of animals used for this study, we designed the experimental protocol by consulting previous studies on assessment of neuroprotections in the rabbit spinal cord ischemia model of infrarenal aortic occlusion. The same eight animals per group were chosen in our experimental protocol as other studies.15,16
Moreover, the expected statistical differences were obtained according to this experimental protocol.
Animals and Surgical Preparation
After an overnight fast with unrestricted access to water, the rabbits were anesthetized with pentobarbital sodium (30 mg/kg, IV) and allowed to breathe spontaneously and inhaled oxygen by face mask at a flow rate of 2 l/min. The lactated Ringer’s solution (4 ml · kg−1 · h−1) was infused intravenously. A 22-gauge catheter was inserted into the ear artery to measure the proximal blood pressure. Another catheter was inserted into the left femoral artery to measure the distal blood pressure. Blood pressure was monitored continuously by using a calibrated pressure transducer connected to an invasive pressure monitor (Spacelabs Medical Inc., Redmond, WA). Rectal temperature was maintained between 38°C and 39°C by an overhead lamp during the experiments. Arterial blood was sampled at preischemia, 10 min after ischemia, and 10 min after reperfusion, respectively, for the determination of arterial oxygen tension (Pao2), arterial carbon dioxide tension (Paco2), pH, and plasma glucose. Arterial blood gases were measured by means of the OMNI Modular System (AVL List GmbH Medizintechnik, Kleiststrabe, Graz, Austria).
Spinal Cord Ischemia
Spinal cord ischemia was induced by infrarenal aortic occlusion in the rabbits as described in our previous studies.15,16
Briefly, animals were placed in supine position. The abdominal aorta was exposed at the level of the left renal artery through a 3- to 4-cm-long medial incision. Spinal cord ischemia was induced with the aorta clamping with a bulldog clamp just below the renal artery, and 400 units of heparin was administered 5 min before the aortic occlusion. Obstruction of the blood flow lasted for 20 min. Then the bulldog clamp was removed, and the abdominal wall was closed with wound clips. Local anesthetic infiltration with 0.25% bupivacaine hydrochloride was applied around the wound for postoperative analgesia. Animals were placed on a heating pad to maintain body temperature until recovery from anesthesia. The animals were then returned to their home cage, received prophylactic antibiotic (gentamicin; 40,000 IU once a day for 3 days) and saline (5 ml, twice a day for 5 days) to prevent dehydration. Bladders were voided manually twice a day until normal function returned. Over the course of postsurgery, all animals were monitored carefully for any distress, pain, and discomfort until they were alert, mobile, and could freely access food and water. The animals were then euthanized if they were in extremes.
In experiment 1, the motor function of the hind limb of animals was assessed at 24 h, 48 h and 72 h after reperfusion by an independent observer, who had no prior knowledge of the experimental protocol and was unaware of the grouping. A modified Tarlov criteria was used: 0, no voluntary hind-limb function; 1, only perceptible joint movement; 2, active movement but unable to stand; 3, able to stand but unable to walk; 4, complete normal hind-limb motor function.
Hematoxylin and Eosin Staining
In experiment I, a histopathologic evaluation was performed in the spinal cord at 72 h after reperfusion. After all animals were reanesthetized with 40 mg/kg sodium pentobarbiturate, transcardiac perfusion and fixation was performed with 1000 ml heparinized saline followed by 500 ml of 10% buffered formalin. The lumbar spinal cord (L4–6 segments) was removed and refrigerated in 10% phosphate-buffered formalin for 48 h. After dehydration in the graded ethanol and butanol, the spinal cord was embedded in the paraffin. Coronal sections of the spinal cord (L4 segment) were cut at a thickness of 6 μm and stained with hematoxylin and eosin. Neuronal injury was evaluated with a light microscope at a magnification of ×100 by an observer who was unaware of grouping. Ischemic feature changes of motor neurons were identified by shrunken cellular bodies, a disappearance of Nissl granules, an intensely eosinophilic cytoplasm, and triangular and pyknotic nuclei. The remaining normal neurons in the ischemic ventral spinal cord in each animal, judged by their morphological appearance, were counted in three sections selected randomly from the rostral, middle, and caudal levels of the L4 segment and then averaged. The numbers of normal motor neurons per section in the anterior spinal cord (anterior to an imaginary line drawn through the central canal perpendicular to the vertical axis) were compared among five groups.
TUNEL Staining and Quantification of Apoptosis
To detect DNA fragmentation in the nuclei of the cells, we applied a kit for immunohistochemical detection and quantification of apoptosis, based on labeling of DNA strand breaks, according to instruction manual (Roche Diagnostics GmbH, Mannheim, Germany) and protocol described in our previous study.17
After deparaffinization, the nuclei of the tissue sections were stripped of proteins by incubation with 20 μg/ml proteinase K for 10 min. After being treated with 3% hydrogen peroxide (H2
) in distilled water for 5 min, they were incubated with 50 μl of terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) reaction mixture (enzyme solution:label solution = 1:9) for 60 min at 37°C in a humidified atmosphere in the dark. The tissue sections were washed three times with 0.01 m phosphate-buffered saline and were analyzed under a BX-60 fluorescence microscope (Olympus Corporation, Tokyo, Japan). To determine the number of motor neurons that underwent apoptosis, a blinded researcher counted the motor neurons that were positive or negative in the TUNEL staining.
Serum Concentrations of HMGB1
In experiment 2, blood samples (1 ml) were collected from the femoral vein at preischemia, at the onset of reperfusion, and at 2 h, 6 h, 24 h, 48 h, and 72 h after reperfusion, respectively. Serum was isolated after centrifugation at 2,000g
for 20 min at 4°C. After centrifugation, serum was frozen at −80°C until enzyme-linked immunosorbent assay (ELISA) analysis was performed. The serum HMGB1 concentrations were measured using a commercial ELISA kit specific for rabbit HMGB1 (Central Institute, Shino-Test, Kanagawa, Japan) as described in previous study.18
Spinal Cord HMGB1 Contents
At 72 h after reperfusion, the lumbar spinal cord (L4–6 segments) of all animals were removed under anesthesia with 40 mg/kg sodium pentobarbiturate. Spinal cord samples were snap frozen in liquid nitrogen immediately after harvest and stored at −80°C pending protein extraction. Tissue samples were homogenized in a test tube containing 1 ml of immunoprecipitation assay buffer with 10 μl of protease inhibitor cocktail and placed on ice for 30 min. The samples were then sonicated for 20 s and incubated on ice for an additional 30 min. These samples were then centrifuged at 10,000 g for 10 min. The supernatants were then decanted, aliquoted, and frozen (−80°C) until analysis with ELISA. ELISA kits (Central Institute, Shino-Test) using the quantitative sandwich enzyme immunoassay technique were used to determine levels of HMGB1 in the protein extracts. The ELISA plates were read on a Model 550-microplate reader (Bio-Rad Laboratories, Hercules, CA). The protein content values were extrapolated off the standard curve and normalized to the total protein concentration, which was determined with a bicinchoninic acid Protein Assay Reagent Kit (Pierce Biotechnology Inc., Rockford, IL).
Spinal cord sections were examined by two independent and blinded investigators. SPSS 11.0 for Windows (SPSS Inc., Chicago, IL) was used to conduct statistical analyses. All values, except for neurologic scores, are presented as mean ± SEM. The physiologic data and the serum HMGB concentration were analyzed using two-way repeated-measures (time and group) analysis of variance followed by the post hoc Student-Newman-Keuls test. The spinal cord HMGB1 content were analyzed by one-way analysis of variance, and between-group differences were detected with Independent-Samples t test. The scores of hind-limb motor function were expressed as median (minimum-maximum value). The score of hind-limb motor function, the number of normal neurons, and the number of TUNEL-positive motor neurons in the anterior spinal cord were analyzed with Kruskal-Wallis test followed by the Mann-Whitney U test with Bonferroni correction. Correlations of the spinal cord HMGB1 levels and the numbers of apoptotic motor neurons in anterior horns of spinal cords were analyzed using Spearman’s rank correlation test. A P value of less than 0.05 was considered to be statistically significant.
The hemodynamics, rectal temperature, arterial pH, Paco2, Pao2, and blood glucose concentrations were similar in all groups at any time point. The distal blood pressure was approximately 75 to 83 mmHg (10 to 11 kPa) before blocking the abdominal aorta and decreased to 7 to 12 mmHg (1.0 to 1.1 kPa) during the time artery was clamped. Ten minutes after the beginning of reperfusion, the value of the distal blood pressure was recovered to 90–93% preischemic level (data not shown).
Treatment with EP within 6 h after Reperfusion Improves Neurologic Outcomes
All animals survived until the final neurologic behavior assessment at 24 h, 48 h, and 72 h after reperfusion. The hind-limb motor function scores of five groups at 24 h, 48 h, and 72 h after reperfusion are shown in figure 1
. In control group, all animals developed complete paraplegia of the hindlimbs (grade 1) at 72 h after reperfusion. The neurologic status of the EP group was significantly improved compared to that of control group at 24 h, 48 h, and 72 h after reperfusion (P
= 0.029, 0.001, 0.004, respectively). The neurologic outcome of EP-6 h group was better than that of control group at 48 h and 72 h after reperfusion (P
= 0.009 and 0.008, respectively). However, the hind-limb motor function scores in EP-12 h and EP-24h groups were similar to the control group at 24 h, 48 h, and 72 h after reperfusion. Moreover, there were no difference in the Tarlov scores between the EP group and EP-6 h group at 48 h and 72 h after reperfusion.
Treatment with EP within 6 h after Reperfusion Increases the Numbers of Normal Motor Neurons
The representative micrographs of hematoxylin and eosin staining in the ventral horn of L4 spinal cord segments 72 h after reperfusion are shown in figures 2A–C
. The numbers of normal motor neurons in the anterior horn of spinal cord are shown at 72 h after reperfusion in figure 2D
. The numbers of normal neurons in EP and EP-6 h groups were more than that in control group (P
= 0.001 and 0.001, respectively), whereas the numbers of normal neurons in EP-12 h and EP-24h groups were similar to that in control group (P
= 0.344 and 0.874, respectively). However, there were no significant differences in the numbers of normal neurons between EP group and EP-6 h group (P
Treatment with EP within 6 h after Reperfusion Alleviates Motor Neuron Apoptosis
Photographs of TUNEL staining of the spinal cords are shown in figure 3
. TUNEL staining identified no apoptotic cells in the cord sections of the sham-operated animals (fig. 3A
). In the spinal cords from the control group, numerous motor neurons were strongly positive for TUNEL staining (fig. 3B
). In the samples from the EP group, however, a few of the motor neurons were positive for TUNEL staining (fig. 3C
For quantitative measurement, the number of motor neurons that were positive or negative for TUNEL was recorded in each specimen in a blind fashion. Administration of EP at 30 min before ischemia or at 6 h after reperfusion significantly reduced the total number of apoptotic motor neurons compared with that in the control group (P
= 0.001 and 0.001, respectively). No significant difference in the total number of apoptotic motor neurons was found between the EP and EP-6 h groups (P
= 0.628). The number of TUNEL-positive motor neurons at 72 h after reperfusion in the EP-12 h and EP-24h groups was similar to that in C group (fig. 3D
Serum HMGB1 Concentrations
As shown in figure 4
, the serum HMGB1 concentrations of the sham animals were unchanged in the period of the experimental procedure. However, the concentration of serum HMGB1 in both control group and EP group significantly increased at 2 h after reperfusion compared with that of preischemia and remained at higher levels thereafter (P
< 0.05). Serum HMGB1 concentrations of the animals treated with EP were significantly lower than that of control animals from 2 h to 72 h after reperfusion (P
The Contents of HMGB1 in Spinal Cord Tissue at 72 h after Reperfusion
At 72 h after reperfusion, the HMGB1 contents of spinal cord tissue in animals treated with EP were significantly lower than those of control group (P
= 0.000) (fig. 5A
). The HMGB1 contents of spinal cord tissue correlated well with the numbers of apoptotic motor neurons in the anterior spinal cord at 72 h after reperfusion (r
= 0.915, P
= 0.000, fig. 5B
There is a wealth of evidence to suggest that the systemic inflammatory response associated with I/R injury contributes to the morbidity and mortality associated with repair of thoracoabdominal aortic aneurysms.19
Administration of high-dose methylprednisolone, a glucocorticoid steroid, after spinal cord injuries has been considered the only widely accepted pharmacological therapy currently in use in humans. The principal mechanism by which methylprednisolone confers neuroprotection is likely through its ability to inhibit posttraumatic lipid peroxidation and inflammatory responses. Although clinical results were initially promising, there have been growing concerns that the modest neurologic improvements seen with high-dose methylprednisolone treatment in injured patients are not worth the associated risks.20
Therefore, there is a critical need to develop new pharmacologic therapies for treatment of spinal cord injuries through inhibiting inflammatory responses.
EP has been shown to exert an effective antiinflammatory effect through inhibiting the expression of various proinflammatory mediators as well as circulating levels of HMGB1 in a variety of in vitro
and in vivo
Recently, EP has been reported to provide a neuroprotective effect on cerebral ischemia, in which it was found to be effective when administered as late as 24 h after I/R. The significant neuroprotection was accompanied by the suppression of microglial activation and proinflammatory cytokines. These results suggest that EP has a strong protective effect with a wide therapeutic window related to its antiinflammatory action.9
In the current study, we show that EP significantly attenuated spinal cord I/R injury when administered at 30 min before ischemia or at 6 h after the onset of reperfusion. The extended therapeutic window implies that the EP affords neuroprotection via
a mechanism that modulates the delayed damaging processes in the postischemic spinal cord.
HMGB1 is a nonhistone nuclear protein with dual function. Inside the cells, HMGB1 binds DNA and plays a role in transcriptional regulation. Outside the cell, HMGB1 serves as a late cytokine-like mediator of systemic inflammation.13
HMGB1 can activate inflammatory pathways when released from ischemic cells. Studies indicate that HMGB1 acts as an early mediator of inflammation and organ damage in hepatic I/R injury. HMGB1 levels were increased during liver I/R as early as 1 h after reperfusion and then increased in a time-dependent manner up to 24 h. Inhibition of HMGB1 activity with neutralizing antibody significantly decreased liver damage after I/R, whereas administration of recombinant HMGB1 worsened I/R injury.23,24
Moreover, HMGB1 is massively released extracellularly and plays a cytokine-like function in the postischemic brain.10–12
HMGB1, as a mediator of postischemic brain damage, plays a critical role in the development of brain infarction through the amplification of plural inflammatory responses in the ischemic region and could be an outstandingly suitable target for the treatment.25
Intravenous injection of neutralizing anti-HMGB1 monoclonal antibody provides a novel therapeutic strategy for ischemic stroke.26
In addition, serum HMGB1 levels were significantly elevated in patients with myocardial ischemia and cerebral ischemia, suggesting that systemic HMGB1 levels are elevated in human ischemic disease.27
In this study, serum HMGB1 concentrations were increased during spinal cord I/R as early as 2 h after reperfusion and then increased in a time-dependent manner up to 72 h. Moreover, spinal cord HMGB1 contents were increased at 72 h after reperfusion. Those results indicate that HMGB1 was involved in the proinflammatory stress response to I/R injuries of spinal cord manifested as a time-dependent production of HMGB1 after spinal cord I/R in rabbits.
Obviously, inhibition of HMGB1 secretion or release represents a novel and promising strategy for the therapy of I/R injuries.25
EP was the first described pharmacological inhibitor for HMGB1 secretion.5
In the current study, EP attenuated serum HMGB1 levels after spinal cord I/R injury when administered at 30 min before ischemia. To assess the efficacy of treatment with EP, we performed an analysis with the “last observation carried forward” method. The HMGB1 contents of spinal cord tissue in the animals treated with EP at 72 h after reperfusion were found to be significantly lower than those of control ones. In line with this, EP provided a strong protective effect with a wide therapeutic window related to its inhibitory effect on HMGB1 release.
On the other hand, apoptosis has been demonstrated to be an important mode of neuron death in the ischemic spinal cord and to play an important role in delayed paraplegia in the rabbit model of aortic occlusion.3,28
In this study, apoptotic cells were detected on the basis of positive TUNEL staining, with the fluorescent nucleus in a granular pattern. We used this method because it is a highly sensitive and specific means of identifying DNA fragmentation. As noted, numerous apoptotic motor neurons were observed in the spinal cords of the control animals. The total number of TUNEL-positive motor neurons was reduced significantly after EP treatment. The results showed that EP alleviated neuron apoptosis induced by spinal cord I/R. In line with this, the animals treated with EP had better neurologic outcomes than those in the control ones. Moreover, at 72 h after reperfusion, the HMGB1 levels of spinal cord tissue in animals treated with EP were significantly lower than those of control group. The HMGB1 levels of spinal cord tissue correlated well with the numbers of apoptotic motor neurons in the anterior spinal cord. Together, these results indicate that inhibition of HMGB1 release by EP resulted in less apoptosis and better functional recovery. In accordance with our experimental results, the relationship between apoptosis and HMGB1 release in macrophages and other cells was investigated in in vitro
studies, and those results indicated that HMGB1 release from macrophages was correlated with the occurrence of apoptosis and suggested that these processes reflect common mechanisms and can occur concomitantly.29
However, other studies have shown that HMGB1 production was downstream of apoptosis on the final common pathway to organ damage in severe sepsis.30
Thus, the crosstalks between HMGB1 and apoptosis need to be further explored.
Several limitations of this study merit comment. First, we cannot conclude whether neuronal apoptosis was inhibited or simply delayed by EP intervention during the 72 h recovery interval in our study. On the basis of the data from previous studies, neuronal apoptosis begins as early as 4 h and lasts for a couple of weeks after spinal cord injury.28
Our results showed that administration of EP significantly reduced the total number of apoptotic motor neurons at 72 h after reperfusion, which indicated that EP alleviated spinal cord I/R through, at least, delayed neuronal apoptosis. A longer recovery period might be necessary for the assessments of the inhibiting effects of EP on apoptosis. Second, it is not known whether earlier treatment with EP affords a better neuroprotective effect against spinal cord I/R than 6 h after reperfusion or multiple administration (for example, once a day for 3 days). Those issues would be addressed in the future study.
In conclusion, to our best knowledge, our study demonstrates for the first time that HMGB1 release plays an important role in spinal cord I/R damage and is involved in motor neuronal apoptosis. EP affords strong protection against transient spinal cord I/R injury with a wide therapeutic window. This protective effect of EP is related to the inhibition of HMGB1 release induced by spinal cord I/R. These data suggest a new therapeutic possibility for treatment of postischemic injury with EP. Future research should be directed toward developing a better understanding of the cross-talk between HMGB1 and apoptosis, as this ultimately might lead to therapeutic strategies for humans.
The authors thank Yan Lu, Ph.D., Professor, Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University (Xi’an, China), for his critical reading of the manuscript.
1. Zvara DA: Thoracoabdominal aneurysm surgery and the risk of paraplegia: contemporary practice and future directions. J Extra Corpor Technol 2002; 34:11–7
2. Keane RW, Davis AR, Dietrich WD: Inflammatory and apoptotic signaling after spinal cord injury. J Neurotrauma 2006; 23:335–44
3. Beattie MS, Farooqui AA, Bresnahan JC: Review of current evidence for apoptosis after spinal cord injury. J Neurotrauma 2000; 17:915–25
4. Beattie MS: Inflammation and apoptosis: Linked therapeutic targets in spinal cord injury. Trends Mol Med 2004; 10:580–3
5. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, Tracey KJ: Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 2002; 99:12351–6
6. Woo YJ, Taylor MD, Cohen JE, Jayasankar V, Bish LT, Burdick J, Pirolli TJ, Berry MF, Hsu V, Grand T: Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia. J Thorac Cardiovasc Surg 2004; 127:1262–9
7. Taylor MD, Grand TJ, Cohen JE, Hsu V, Liao GP, Zentko S, Berry MF, Gardner TJ, Woo YJ: Ethyl pyruvate enhances ATP levels, reduces oxidative stress and preserves cardiac function in a rat model of off-pump coronary bypass. Heart Lung Circ 2005; 14:25–31
8. Kim JB, Yu YM, Kim SW, Lee JK: Anti-inflammatory mechanism is involved in ethyl pyruvate-mediated efficacious neuroprotection in the postischemic brain. Brain Res 2005; 1060:188–92
9. Yu YM, Kim JB, Lee KW, Kim SY, Han PL, Lee JK: Inhibition of the cerebral ischemic injury by ethyl pyruvate with a wide therapeutic window. Stroke 2005; 36:2238–43
10. Kim JB, Sig Choi J, Yu YM, Nam K, Piao CS, Kim SW, Lee MH, Han PL, Park JS, Lee JK: HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 2006; 26:6413–21
11. Faraco G, Fossati S, Bianchi ME, Patrone M, Pedrazzi M, Sparatore B, Moroni F, Chiarugi A: High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro
and in vivo
. J Neurochem 2007; 103:590–603
12. Kim JB, Lim CM, Yu YM, Lee JK: Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J Neurosci Res 2008; 86:1125–31
13. Yamada S, Maruyama I: HMGB1, a novel inflammatory cytokine. Clin Chim Acta 2007; 375:36–42
14. Ulloa L, Fink MP, Tracey KJ: Ethyl pyruvate protects against lethal systemic inflammation by preventing HMGB1 release. Ann N Y Acad Sci 2003; 987:319–21
15. Dong H, Xiong L, Zhu Z, Chen S, Hou L, Sakabe T: Preconditioning with hyperbaric oxygen and hyperoxia induces tolerance against spinal cord ischemia in rabbits. Anesthesiology 2002; 96:907–12
16. Nie H, Xiong L, Lao N, Chen S, Xu N, Zhu Z: Hyperbaric oxygen preconditioning induces tolerance against spinal cord ischemia by upregulation of antioxidant enzymes in rabbits. J Cereb Blood Flow Metab 2006; 26:666–74
17. Wang Q, Gou X, Xiong L, Jin W, Chen S, Hou L, Xu L: Trans-activator of transcription-mediated delivery of NEP1-40 protein into brain has a neuroprotective effect against focal cerebral ischemic injury via
inhibition of neuronal apoptosis. Anesthesiology 2008; 108:1071–80
18. Yamada S, Inoue K, Yakabe K, Imaizumi H, Maruyama I: High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. Clin Chem 2003; 49:1535–7
19. Fiane AE, Videm V, Lingaas PS, Heggelund L, Nielsen EW, Geiran OR, Fung M, Mollnes TE: Mechanism of complement activation and its role in the inflammatory response after thoracoabdominal aortic aneurysm repair. Circulation 2003; 108:849–56
20. Sayer FT, Kronvall E, Nilsson OG: Methylprednisolone treatment in acute spinal cord injury: The myth challenged through a structured analysis of published literature. Spine J 2006; 6:335–43
21. Lim SC, Choi JE, Kim CH, Duong HQ, Jeong GA, Kang HS, Han SI: Ethyl pyruvate induces necrosis-to-apoptosis switch and inhibits high mobility group box protein 1 release in A549 lung adenocarcinoma cells. Int J Mol Med 2007; 20:187–92
22. Fink MP: Ethyl pyruvate: A novel anti-inflammatory agent. J Intern Med 2007; 261:349–62
23. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, Yang H, Li J, Tracey KJ, Geller DA, Billiar TR: The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201:1135–43
24. Watanabe T, Kubota S, Nagaya M, Ozaki S, Nagafuchi H, Akashi K, Taira Y, Tsukikawa S, Oowada S, Nakano S: The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. J Surg Res 2005; 124:59–66
25. Wang H, Li W, Goldstein R, Tracey KJ, Sama AE: HMGB1 as a potential therapeutic target. Novartis Found Symp 2007; 280:73–85
26. Liu K, Mori S, Takahashi HK, Tomono Y, Wake H, Kanke T, Sato Y, Hiraga N, Adachi N, Yoshino T, Nishibori M: Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 2007; 21:3904–16
27. Goldstein RS, Gallowitsch-Puerta M, Yang L, Rosas-Ballina M, Huston JM, Czura CJ, Lee DC, Ward MF, Bruchfeld AN, Wang H, Lesser ML, Church AL, Litroff AH, Sama AE, Tracey KJ: Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006; 25:571–4
28. Hayashi T, Sakurai M, Abe K, Sadahiro M, Tabayashi K, Itoyama Y: Apoptosis of motor neurons with induction of caspases in the spinal cord after ischemia. Stroke 1998; 29:1007–12
29. Jiang W, Bell CW, Pisetsky DS: The relationship between apoptosis and high-mobility group protein 1 release from murine macrophages stimulated with lipopolysaccharide or polyinosinic-polycytidylic acid. J Immunol 2007; 178:6495–503
30. Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston JM, Miller E, Lin X, Sherry B, Kumar A, Larosa G, Newman W, Tracey KJ, Yang H: Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006; 203:1637–42
This article has been cited 12 time(s).
Brain ResearchBeneficial effects of hydrogen-rich saline against spinal cord ischemia-reperfusion injury in rabbitsBrain Research
International Journal of Developmental NeuroscienceEthyl pyruvate protects against lipopolysaccharide-induced white matter injury in the developing rat brainInternational Journal of Developmental Neuroscience
NeuroscienceEthyl Pyruvate Ameliorates Intracerebral Hemorrhage-Induced Brain Injury Through Anti-Cell Death and Anti-Inflammatory MechanismsNeuroscience
Neurochemical ResearchImprovement of Hypoxia-Ischemia-Induced White Matter Injury in Immature Rat Brain by Ethyl PyruvateNeurochemical Research
Human & Experimental ToxicologyNeuroprotective effects of alpha-ketoglutarate and ethyl pyruvate against motor dysfunction and oxidative changes caused by repeated 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine exposure in miceHuman & Experimental Toxicology
Journal of Thoracic and Cardiovascular SurgeryIschemic postconditioning protects the spinal cord from ischemia-reperfusion injury via modulation of redox signalingJournal of Thoracic and Cardiovascular Surgery
BiomaterialsTargeted delivery of Neurogenin-2 protein in the treatment for cerebral ischemia-reperfusion injuryBiomaterials
Biochemical and Biophysical Research CommunicationsEthyl pyruvate has a neuroprotective effect through activation of extracellular signal-regulated kinase in Parkinson's disease modelBiochemical and Biophysical Research Communications
Biochemical PharmacologyThe biochemical basis for the anti-inflammatory and cytoprotective actions of ethyl pyruvate and related compoundsBiochemical Pharmacology
Comparison of the Effect of Mexiletine and Methylprednisolone on Neural Function and Histopathological Damage after Transient Spinal Cord Ischemia in Rabbits
Turkish Neurosurgery, 20(1):
Current Opinion in Investigational Drugs
Autophagy inhibition in combination cancer treatment
Current Opinion in Investigational Drugs, 10():
Biochemical and Biophysical Research CommunicationsSpinal high-mobility group box 1 contributes to mechanical allodynia in a rat model of bone cancer painBiochemical and Biophysical Research Communications
© 2009 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.